Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system

International Journal of Pharmaceutics

Volumn 348, Issue 1-2, 2008, Pages 27-34

  Liu, Quan ^a   Fassihi, Reza ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Composite matrix; Controlled release alfuzosin; Gastro retentive system; Texture analysis; Zero order drug delivery

Indexed keywords

ALFUZOSIN; BICARBONATE; CITRIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL; POVIDONE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; PRIORITY JOURNAL; SMALL INTESTINE; ULTRAVIOLET SPECTROSCOPY;

ADRENERGIC ALPHA-ANTAGONISTS; CELLULOSE; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; MECHANICS; METHYLCELLULOSE; POLYETHYLENE GLYCOLS; POLYMERS; QUINAZOLINES; TABLETS; WATER;

EID: 37249007310     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.07.009     Document Type: Article

References (27)

1. Akiyama Y., and Nagahara N. Novel formulation approaches to oral mucoadhesive drug delivery systems. In: Mathiowitz E., Chickering III D.E., and Lehr C.M. (Eds). Bioadhesive Drug Delivery Systems Fundamentals: Novel Approaches and Development (1999), Marcel Dekker, New York 477-505
2. Andrieu, V., Montel, J., Wick, A., 1995. Sustained-release pharmaceutical dosage forms containing alfuzosin hydrochloride. European Patent 0673650, September 27.
3. Burke M., Staton J., Vickers A., Peters E., and Coffin M. A novel method to radiolabel gastric retentive formulations for gamma scintigraphy assessment. Pharm. Res. 24 (2007) 695-704
4. Cooreman M.P., Krausgril P., and Hengels K.J. Local gastric and serum amoxycillin concentrations after different oral application forms. Antimicrob. Agents Chemother. 37 (1993) 1506-1509
5. Costa P., and Lobo J. Modeling and comparison of dissolution profiles. Eur. J. Pharm. 13 (2001) 123-133
6. Dave B.S., Amin A.F., and Patel M.M. Gastroretentive drug delivery system of ranitidine hydrochloride: floatation and in vitro evaluation. AAPS pharmScitech. 5 (2004)
7. Djavan B., and Marberger M. A meta-analysis on the efficacy and tolerability of 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 36 (1999) 1-13
8. Durig T., and Fassihi R. Guar-based monolithic matrix systems: effect of ionizable and non-ionizable substances and excipients on gel dynamics and release kinetics. J. Control. Release 80 (2002) 45-56
9. Flashner-Barak, M., Rosenberger, V., Lerner, Y., 2002. Composition and dosage form for delayed gastric release of alendronate and/or other bisphosphonates. US Patent 6,476,006, November 5.
10. Jamzad S., and Fassihi R. Development of a controlled release low dose class II drug-glipizide. Int. J. Pharm. 312 (2006) 24-32
11. Kamba M., Seta Y., Kusai A., Ikeda M., and Nishimura K. A unique dosage form to evaluate mechanical destructive force in the gastrointestinal tract. Int. J. Pharm. 208 (2000) 61-70
12. Lindner W.D., and Lippold B.C. Drug release from hydrocolloid embeddings with high or low susceptibility to hydrohynamic stress. Pharm. Res. 12 (1995) 1781-1785
13. Maggi, L., Conte, U., Gerenier, P., Vergnault, G., Dufore, A., Jarreau, F.X., Rauch-Desanti, C., 2000. Tablet with controlled release of alfuzosin chlorhydrate. US Patent 6,149,940A, November 21.
14. Moes A.J. Gastroretentive dosage forms. Crit. Rev. Ther. Drug Carrier Syst. 10 (1993) 143-195
15. Moore J.W., and Flanner H.H. Mathematical comparison of dissolution profiles. Pharm. Technol. 20 (1996) 64-74
16. Nur A., and Zhang J. Captopril floating and/or bioadhesive tablets: design and release kinetics. Drug Dev. Ind. Pharm. 26 (2000) 965-969
17. Penners, G., Lustig, K., Petersen-von Gehr, J., 1997. Expandable pharmaceutical forms. US Patent 5651985, July 29.
18. Physicians' Desk Reference (PDR), 59th ed., 2005. Thomson PDR, Montvale, NJ.
19. Rossi C., Kortmann B.M., and Sonke G.S. α-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J. Urol. 165 (2001) 38-41
20. Singh B.M., and Kim K.H. Floating drug delivery system: an approach to oral controlled drug delivery via gastic rentention. J. Control. Release 63 (2000) 235-239
21. Sriamornsak P., Thirawong N., and Puttipipatkhachorn S. Morphology and buoyancy of oil-entrapped calcium pectinate gel beads. AAPS J. 6 (2004)
22. Steingoetter A., Weishaupt D., Kunz P., Mader K., Lengsfeld H., Thumshirn M., Boesiger P., Fried M., and Schwizer W. Magnetic resonance imaging for the in vivo evaluation of gastric-retentive tablets. Pharm. Res. 20 (2003) 2001-2007
23. Streubel A., Siepmann J., and Bodmeier R. Floating microparticles based on low density foam powder. Int. J. Pharm. 241 (2002) 279-292
24. Talukder R., and Fassihi R. Gastroretentive delivery systems: hollow beads. Drug Dev. Ind. Pharm. 30 (2004) 405-412
25. Yang L., and Fassihi R. Zero-order release kinetics from a self-correcting floatable asymmetric configuration drug delivery system. J. Pharm. Sci. 85 (1996) 170-173
26. Yang L., and Fassihi R. Modulation of diclofenac release from a totally soluble controlled release drug delivery system. J. Control. Release 44 (1997) 135-140
27. Yang L., Venkatesh G., and Fassihi R. Compaction simulator study of a novel triple-layer tablet matrix for industrial tableting. Int. J. Pharm. 152 (1997) 45-52